Sanders Morris Harris LLC Purchases 6,296 Shares of Merck & Co., Inc. $MRK

Sanders Morris Harris LLC raised its position in Merck & Co., Inc. (NYSE:MRK) by 399.0% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 7,874 shares of the company’s stock after buying an additional 6,296 shares during the quarter. Sanders Morris Harris LLC’s holdings in Merck & Co., Inc. were worth $1,157,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of MRK. Susquehanna Fundamental Investments LLC purchased a new stake in Merck & Co., Inc. during the second quarter worth about $11,470,000. Russell Investments Group Ltd. grew its position in Merck & Co., Inc. by 2.0% during the second quarter. Russell Investments Group Ltd. now owns 2,578,024 shares of the company’s stock worth $331,931,000 after buying an additional 51,393 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in Merck & Co., Inc. by 7.0% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 6,184,340 shares of the company’s stock worth $794,577,000 after buying an additional 402,011 shares during the period. Talon Private Wealth LLC purchased a new position in Merck & Co., Inc. in the second quarter valued at about $995,000. Finally, The Manufacturers Life Insurance Company increased its holdings in Merck & Co., Inc. by 12.3% in the second quarter. The Manufacturers Life Insurance Company now owns 2,073,176 shares of the company’s stock valued at $266,403,000 after buying an additional 227,589 shares in the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on MRK. Morgan Stanley reduced their price target on shares of Merck & Co., Inc. from $179.00 to $177.00 and set an “overweight” rating for the company in a research report on Wednesday, October 7th. JPMorgan Chase & Co. upped their price target on Merck & Co., Inc. from $150.00 to $165.00 and gave the stock an “overweight” rating in a report on Monday, October 5th. UBS Group upped their price target on Merck & Co., Inc. from $145.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 20th. Daiwa Securities Group raised Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price objective for the company in a research note on Wednesday, August 12th. Finally, Berenberg Bank lifted their price objective on Merck & Co., Inc. from $127.00 to $137.00 and gave the stock a “hold” rating in a report on Friday, September 11th. Seventeen research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and a consensus price target of $151.92.

Merck & Co., Inc. Price Performance

Shares of MRK stock traded up $5.49 during trading hours on Wednesday, hitting $147.47. The company’s stock had a trading volume of 9,795,556 shares, compared to its average volume of 10,626,400. The business has a fifty day moving average of $144.91 and a 200-day moving average of $128.93. The stock has a market cap of $363.83 billion, a price-to-earnings ratio of 117.97, a P/E/G ratio of 6.72 and a beta of 0.21. Merck & Co., Inc. has a twelve month low of $82.01 and a twelve month high of $156.92. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The business had revenue of $16.61 billion during the quarter, compared to analysts’ expectations of $16.37 billion. During the same period last year, the company posted $2.13 EPS. The company’s revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities research analysts anticipate that Merck & Co., Inc. will post 2.66 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th were issued a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date was Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio is 272.00%.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Keytruda could support upcoming results: Analysts expect continued Keytruda sales growth, contributions from earlier-stage launches and expanded indications to help Merck’s third-quarter revenue and earnings. Will Keytruda Continue to Aid Merck’s Top Line in Q3 Earnings?
• Positive Sentiment: Potentially faster cancer-vaccine manufacturing: CEO Rob Davis said the personalized cancer vaccine being developed with Moderna should become faster to manufacture over time. He described the current process as complex but increasingly standardized, which could improve the program’s commercial scalability. Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
• Positive Sentiment: Pipeline visibility improved: Merck will present first-time Phase 3 results from three pivotal oncology trials and more than 90 additional abstracts at the upcoming ESMO 2026 conference. Positive data could strengthen confidence in products that may eventually help offset Keytruda’s patent and competitive pressures. Merck Showcases First-Time Pivotal Phase 3 Results
• Positive Sentiment: Analyst endorsement: Leerink Partners initiated or reiterated a Buy rating, adding support to the positive near-term sentiment around Merck’s earnings outlook and oncology pipeline. Merck Gets a Buy from Leerink Partners
• Neutral Sentiment: Board appointment: Merck elected Paul J. Diaz to its board of directors. The move adds leadership and healthcare-sector experience but is unlikely to materially change near-term earnings expectations. Paul J. Diaz Elected to Merck Board
• Negative Sentiment: Longer-term Keytruda risk: Biosimilar competition is expected to emerge in 2028–2029, creating a significant future threat to Merck’s largest product and increasing the importance of successful pipeline launches.
• Negative Sentiment: Some earnings estimates were reduced: Erste Group lowered its FY2026 EPS estimate to $2.73 from $2.75 and its FY2027 estimate to $9.47 from $9.52, signaling modest pressure on forecasts. Merck analyst estimates

Insider Activity at Merck & Co., Inc.

In other news, EVP Richard R. Deluca sold 20,784 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $130.43, for a total value of $2,710,857.12. Following the sale, the executive vice president directly owned 134,703 shares in the company, valued at $17,569,312.29. This represents a 13.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP David Williams sold 52,847 shares of the company’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the sale, the executive vice president owned 31,716 shares in the company, valued at $4,084,069.32. This represents a 62.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 228,238 shares of company stock valued at $29,977,783 in the last ninety days. 0.17% of the stock is owned by insiders.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.